Danaher acquires Masimo

Danaher Corporation has announced plans to acquire Masimo Corporation in a $9.9 billion transaction that will bolster its diagnostics portfolio. The Washington-based Danaher, known for its science and technology-led innovations, aims to integrate Masimo's advanced patient monitoring technologies into its diagnostics segment. The acquisition involves a cash payment of $180 per share for all of Masimo's common stock, which Danaher will fund through its existing cash reserves and debt financing.

The acquisition values Masimo at nearly 18 times its projected 2027 EBITDA. Danaher’s Executive Vice President Julie Sawyer Montgomery highlighted that Masimo's expertise in pulse oximetry and patient monitoring aligns with Danaher's strategic objectives, envisioning enhanced capabilities in diagnostics. Masimo's CEO, Katie Szyman, expressed that the merger would leverage Danaher's commitment to innovation and broaden Masimo's reach in acute care markets.

Masimo will continue as an independent entity within Danaher’s Diagnostics segment, joining other subsidiaries like Radiometer and Beckman Coulter. The merger, slated for completion in the latter half of this year pending shareholder approval, is expected to elevate Masimo's adjusted diluted earnings and drive long-term core revenue growth. Financial projections estimate increased earnings per share of $0.15 to $0.20 in the first year and up to $0.70 by year five, with anticipated synergies further enhancing profitability.

The move is set against a backdrop of growing demand in the medical technology sector, where companies are racing to integrate cutting-edge diagnostic tools within their offerings. Danaher's acquisition of Masimo reflects a broader strategic trend of consolidation aimed at capturing market share in the rapidly evolving diagnostics landscape. The acquisition also underscores a competitive dynamic where large players seek to enhance their technology bases through strategic acquisitions.

Key next steps include obtaining regulatory approvals and securing Masimo shareholder consent, which are critical to finalizing the transaction by the disclosed timeline. Danaher’s acquisition underscores a continued focus on expanding its footprint in the healthcare and diagnostics field, where innovations in patient monitoring technologies are pivotal in addressing evolving healthcare needs.